biotech / news / / Barchart
LLY stock has increased 28.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 30.6%.
Eli Lilly raised its 2026 revenue guidance to $82–$85 billion and adjusted EPS to $35.50–$37.
KEY POINTS
- Q1 2026 revenue grew 56% year-over-year, driven by Mounjaro and Zepbound generating $12.8 billion in sales.
- Newly launched Foundayo (orforglipron) already has over 20,000 patients and 8,000 prescribers.
- Consensus analyst rating is 'Strong Buy,' with a mean price target reflecting 23.9% upside.
- Barclays recently raised Eli Lilly's price target to $1,400, maintaining an 'Overweight' rating.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →